Cardiac Biomarkers Testing Devices - Market Insights, Competitive Landscape, and Market Forecast - 2030

Cardiac Biomarkers Testing Market By Product Type (Instruments and Reagents & Kits), Biomarker Type (Troponin, Creatine Kinase-Mb, B-Type Natriuretic Peptide, Myoglobin, and Others]), Application (Acute Coronary Syndrome, Congestive Heart Failure, Myocardial Infarction, and Others), End-User (Hospitals, Pathology Labs, and Others), and Geography is expected to grow at a steady CAGR forecast till 2028 owing to the rising geriatric population and increasing need for early disease diagnosis.

The global cardiac biomarkers testing market was valued at USD 3.50 billion in 2022, growing at a CAGR of 7.77% during the forecast period from 2023 to 2028 to reach USD 5.48 billion by 2028. Factors such as the increasing prevalence of cardiovascular diseases, the growing need for early disease diagnosis, the rising aging population, and the advancement in research in identifying novel clinically-relevant cardiac biomarkers are stimulating the growth of the cardiac biomarker testing market positively.

Cardiac Biomarkers Testing Market Dynamics:

As per the data provided by the World Health Organization (2022), cardiovascular diseases (CVDs) are the leading cause of death across the globe, accounting for an estimated 17.9 million lives each year. Some of the CVDs include myocardial infarction, congestive heart failure, acute coronary syndrome, and other conditions. Furthermore, the same data by the WHO presented that over four out of five CVD deaths list strokes and heart attacks as the main cause and one-third of these deaths are said to occur prematurely in people below 70 years of age. The data also states that more than three-quarters of CVD deaths take place in low- and middle-income countries.

According to the data provided by the European Society for Cardiology (ESC) (2022), each year cardiovascular disease (CVD) causes 3.9 million deaths in Europe and over 1.8 million deaths in the European Union. They represent about 45% of all deaths in Europe and 37% in the European Union.

It has been observed that the current diagnostic and triage systems based on clinical history and electrocardiograms are insufficient for the timely diagnosis of cardiovascular diseases. They may result in some patients being misdiagnosed and being administered inappropriate treatment, care, and investigations. In some patients, the diagnosis is delayed resulting in the late administration (or no administration) of essential early treatment.

Therefore, the need for an early diagnosis of cardiovascular diseases is fuelling the demand for cardiac biomarker testing. Cardiac biomarkers are of great importance in the timely, accurate diagnosis and management of cardiovascular disease as well as in improving the prognosis of the disease for the patient. Diagnosis in the golden period is of utmost importance to institute therapy at the earliest and possibly reverse the myocardial damage. Cardiac biomarkers are also a powerful tool for triaging.

However, the lack of sensitivity and specificity to cardiac muscle necrosis continues to be the need to look for newer specific molecules, limited understanding of the biochemistry of the biomarkers, and challenges in sample collection and obtaining results may restrain the growth of the cardiac biomarker testing market during the forecast period.

Cardiac Biomarker Testing Market Segment Analysis:

Cardiac Biomarker Testing Market by Product Type (Instruments and Reagents & Kits), Biomarker Type (Troponin, Creatine Kinase-MB, Natriuretic Peptide, Myoglobin, and Others]), Application (Acute Coronary Syndrome, Congestive Heart Failure, Myocardial Infarction, and Others), End-User (Hospitals, Pathology Labs, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World).

In the biomarker type segment of the cardiac biomarker testing devices market, the troponin category of cardiac biomarkers is predicted to account for the largest market revenue share. This can be ascribed to the fact that it is considered the best cardiac biomarker among all other cardiac biomarker types. This protein is by far the most commonly used biomarker and has the highest known sensitivity.

Troponin enters the bloodstream soon after a heart attack and remains in the bloodstream for a longer period as compared to other biomarkers. Two forms of troponin may be measured- troponin T and troponin I. Troponin I is considered to be highly specific to the heart and stays higher longer than creatinine kinase-MB. The latest guidelines by the American Heart Association (AHA) mention this biomarker to be the best biomarker for finding a heart attack.

Furthermore, in some patients the electrocardiographic evidence of myocardial infarction remains unclear; in such cases, troponin cardiac biomarkers are extensively used.

North America is expected to dominate the Overall Cardiac Biomarkers Testing Market:

Among all the regions, North America is expected to amass the largest share of the cardiac biomarker testing market. The growing prevalence of cardiovascular diseases, better healthcare facilities coupled with the presence of major market players as well as higher investment in the research and development activities in the region are predicted to be the major influencing factors in driving the overall growth of the cardiac biomarker testing market over the forecast period.

The Centers for Disease Control and Prevention (CDC) 2022, estimated that about 20.1 million adults aged 20 and older had Coronary artery disease (CAD) in the US, in 2020.

Also, the above-mentioned source further stated that in the United States, someone has a heart attack every 40 seconds. Every year, about 805,000 people in the United States have a heart attack. Out of these, 605,000 are a first heart attack, 200,000 happen to people who have already had a heart attack and about 1 in 5 heart attacks are silent - the damage is done, but the person is not aware of it.

As per the information provided by the Centers for Disease Control and Prevention (2022), some of the key risk factors associated with heart diseases are high blood cholesterol, high blood pressure, and smoking. The source further mentioned that about half of Americans (47%) have at least one of these three risk factors.

Therefore, the presence of a large patient population suffering from heart disease is one of the major factors contributing to the North American cardiac biomarker testing market growth.

Moreover, the large presence of key market players as well as the launch of new products in the region as a reason for extensive R&D activities also provides favorable conditions for the growth of the North American cardiac biomarker testing market.

Cardiac Biomarkers Testing Devices Market Key Players:

Some of the key market players operating in the cardiac biomarker testing market include Beckman Coulter, Inc., Siemens Healthcare GmbH, Abbott, bioMérieux SA, F. Hoffmann-La Roche Ltd, Thermo Fischer Scientific Inc., Bio-Rad Laboratories Inc, Eurolyser Diagnostica GmbH, Diagnostic Automation / Cortez Diagnostics, Inc, Randox Laboratories Ltd, Tosoh Corporation, DIALAB GmbH, CardioGenics Holdings Inc, Lepu Medical Technology (Beijing) Co. Ltd., Biosynex and others.

Recent Developmental Activities in Cardiac Biomarkers Testing Market:

• In April 2021, Roche announced the series of five new intended uses for two key cardiac biomarkers using the Elecsys® technology: high-sensitive cardiac troponin T (cTnT-hs) and N-terminal pro-brain natriuretic peptide test (NT-proBNP).

Key Takeaways from the Cardiac Biomarkers Testing Market Report Study

• Market size analysis for cardiac biomarker testing market size (2022), and market forecast for 5 years (2023-2028)
• Top key product/services/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
• Key companies dominating the global cardiac biomarker testing market.
• Various opportunities available for the other competitor in the cardiac biomarker testing market space.
• What are the top-performing segments in 2022? How these segments will perform in 2028?
• Which are the top-performing regions and countries in the current cardiac biomarker testing market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for cardiac biomarker testing market growth in the coming future?

Target Audience who can be benefited from this Cardiac Biomarker Testing Market Report Study

• Cardiac biomarkers testing devices products providers
• Research organizations and consulting companies
• Cardiac biomarkers testing devices -related organization, association, forum, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and Traders dealing in cardiac biomarker testing
• Various End-Users who want to know more about the cardiac biomarker testing market and the latest technological developments in the cardiac biomarker testing market.

Frequently Asked Questions for Cardiac Biomarker Testing Market:

1. What is a cardiac biomarker testing device?

Cardiac biomarkers are protein molecules that are released into the blood after heart damage or heart stress. These biomarkers act as a potential tool in the detection and diagnosis of various cardiovascular diseases.

2. What is the market for global cardiac biomarker testing?

The global cardiac biomarkers testing market was valued at USD 3.50 billion in 2022, growing at a CAGR of 7.77% during the forecast period from 2023 to 2028 to reach USD 5.48 billion by 2028.

3. What are the drivers for the global cardiac biomarker testing market?

The major drivers of the global cardiac biomarker testing market growth are the increasing prevalence of cardiovascular diseases, the growing need for early disease diagnosis, the rising aging population, and the advancement in research in identifying novel clinically-relevant cardiac biomarkers.

4. Who are the key players operating in the global cardiac biomarker testing market?

Some of the key market players operating in the cardiac biomarker testing market include Beckman Coulter, Inc, Siemens Healthcare GmbH, Abbott, bioMérieux SA, F. Hoffmann-La Roche Ltd, Thermo Fischer Scientific Inc, Bio-Rad Laboratories Inc., Eurolyser Diagnostica GmbH, Diagnostic Automation / Cortez Diagnostics, Inc, Randox Laboratories Ltd, Tosoh Corporation, DIALAB GmbH, CardioGenics Holdings Inc, Lepu Medical Technology (Beijing) Co. Ltd., Biosynex and others.

5. Which region has the highest share in the cardiac biomarker testing market?

North America is expected to dominate the overall cardiac biomarker testing market during the forecast period, 2023 to 2028. The accumulation of the highest revenue in the market can be ascribed to the rising prevalence of cardiovascular diseases, increasing focus on research and development activities, and the increasing collaborations between key market players in the region.